> ## Content Index
> Fetch the complete content index at: https://redfiled.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
- URL: https://redfiled.com/incytes-phase-3-retifanlimab-anal-cancer-trial-listed-as-completed/
- Published: 2026-09-02T16:09:33.000Z
- Updated: 2026-09-04T15:35:14.000Z
- Description: The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.
- Author: REDFILED Newsdesk
- Tags: INCY, Clinical

ClinicalTrials.gov record NCT04472429 lists Incyte Corporation's Phase 3 study as COMPLETED, with the entry last updated 2 September 2026.

The trial tested carboplatin-paclitaxel with retifanlimab or placebo in locally advanced or metastatic squamous cell anal carcinoma.

The study is identified as POD1UM-303/InterAACT 2; the indication is squamous cell carcinoma of the anal canal.

The registry entry reports status only and contains no efficacy, safety or regulatory outcome data.

[INCY stock price](https://www.tradingview.com/?ref=redfiled.com) by TradingView

This is a factual summary of a public filing or press release, not investment advice. Verify all figures against the source before acting on them.